Skip to main content
Top
Published in: Digestive Diseases and Sciences 6/2013

01-06-2013 | Original Article

Risk of Complications After a Peptic Ulcer Diagnosis: Effectiveness of Proton Pump Inhibitors

Authors: Sonia Hernández-Díaz, Elisa Martín-Merino, Luis A. García Rodríguez

Published in: Digestive Diseases and Sciences | Issue 6/2013

Login to get access

Abstract

Background

Few studies have evaluated the prevention of upper gastrointestinal complications (UGIC; bleeding or perforation) in patients with uncomplicated peptic ulcer (PU). We assessed the effect of proton pump inhibitors (PPI) in a non-randomized setting. To maximize exchangeability of exposed and unexposed groups we restricted the study to patients with a new diagnosis of PU, i.e., a clear indication. To minimize selection bias we mimicked an intention to treat approach by assessing the effect of PPI prescription after PU diagnosis.

Methods

Within a population of subjects aged 40–84 years from The Health Improvement Network database, 1997–2006, we identified 3,850 patients with incident PU. Among them, we confirmed 74 first UGIC episodes during a mean follow-up of 4 years. Exposure was prescription coverage during the month following PU diagnosis. We performed a nested case–control analysis and compared UGIC cases with 400 controls matched for age, sex, year and duration of follow-up. Relative risks (RR) and 95 % confidence intervals (CI) were estimated.

Results

The overall incidence of UGIC was 4.6 cases/1,000 person-years; it was highest during the months after PU diagnosis, increased with age, and it was higher in men and subjects with Helicobacter pylori infection, anemia, and alcohol use at PU diagnosis. The RR for UGIC associated with PPI prescriptions during the month after PU diagnosis was 0.56 (95 % CI 0.31–1.0). The RR for NSAIDs with and without a PPI was 1.72 (0.68–4.45) and 3.27 (0.85–12.67), respectively.

Conclusions

Findings suggest that prescription of PPIs after a PU diagnosis is associated with a reduced risk of UGIC.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hernández-Díaz S, García Rodríguez L. Incidence of serious upper gastrointestinal bleeding/perforation in the general population: review of epidemiologic studies. J Clin Epidemiol. 2002;55:157–163.PubMedCrossRef Hernández-Díaz S, García Rodríguez L. Incidence of serious upper gastrointestinal bleeding/perforation in the general population: review of epidemiologic studies. J Clin Epidemiol. 2002;55:157–163.PubMedCrossRef
2.
go back to reference García Rodríguez L, Cattaruzzi C, Troncon MG, Agostinis L. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med. 1998;158:33–39.PubMedCrossRef García Rodríguez L, Cattaruzzi C, Troncon MG, Agostinis L. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med. 1998;158:33–39.PubMedCrossRef
3.
go back to reference Hernández-Díaz S, García-Rodríguez L. Overview of epidemiological studies published in the nineties on the association between non-steroidal anti-inflammatory drugs and upper gastrointestinal bleed/perforation. Arch Intern Med. 2000;160:2093–2099.PubMedCrossRef Hernández-Díaz S, García-Rodríguez L. Overview of epidemiological studies published in the nineties on the association between non-steroidal anti-inflammatory drugs and upper gastrointestinal bleed/perforation. Arch Intern Med. 2000;160:2093–2099.PubMedCrossRef
4.
go back to reference Hawkey C, Jeffrey A, Szczepnski L, et al. A comparison of omeprazole and misoprostol for treating and preventing ulcers associated with non-steroidal anti-inflammatory drugs. N Engl J Med. 1998;338:727–734.PubMedCrossRef Hawkey C, Jeffrey A, Szczepnski L, et al. A comparison of omeprazole and misoprostol for treating and preventing ulcers associated with non-steroidal anti-inflammatory drugs. N Engl J Med. 1998;338:727–734.PubMedCrossRef
5.
go back to reference Yeomans N, Tulassay Z, Juhasz L, et al. A comparison of omeprazole and ranitidine for treating and preventing ulcers associated with non-steroidal anti-inflammatory drugs. N Engl J Med. 1998;338:719–726.PubMedCrossRef Yeomans N, Tulassay Z, Juhasz L, et al. A comparison of omeprazole and ranitidine for treating and preventing ulcers associated with non-steroidal anti-inflammatory drugs. N Engl J Med. 1998;338:719–726.PubMedCrossRef
6.
go back to reference Silverstein F, Graham D, Senior J, et al. Misoprostol reduces serious gastrointestinal complication in patients with rheumatoid arthritis receiving non-steroidal anti-inflammatory drugs. Ann Intern Med. 1995;123:241–249.PubMedCrossRef Silverstein F, Graham D, Senior J, et al. Misoprostol reduces serious gastrointestinal complication in patients with rheumatoid arthritis receiving non-steroidal anti-inflammatory drugs. Ann Intern Med. 1995;123:241–249.PubMedCrossRef
7.
go back to reference García-Rodríguez L, Hernández-Díaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology. 2001;12:570–576.PubMedCrossRef García-Rodríguez L, Hernández-Díaz S. Relative risk of upper gastrointestinal complications among users of acetaminophen and nonsteroidal anti-inflammatory drugs. Epidemiology. 2001;12:570–576.PubMedCrossRef
8.
go back to reference Jensen D, Cheng S, Kovacs T, et al. A controlled study of ranitidine for the prevention of recurrent hemorrhage from duodenal ulcer. N Engl J Med. 1994;330:382–386.PubMedCrossRef Jensen D, Cheng S, Kovacs T, et al. A controlled study of ranitidine for the prevention of recurrent hemorrhage from duodenal ulcer. N Engl J Med. 1994;330:382–386.PubMedCrossRef
9.
go back to reference Lai K, Lam S, Chu K, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med. 2002;346:2033–2038.PubMedCrossRef Lai K, Lam S, Chu K, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med. 2002;346:2033–2038.PubMedCrossRef
10.
go back to reference García Rodríguez L, Ruigómez A. Secondary prevention of upper gastrointestinal bleeding associated with maintenance acid-suppressing treatment in patients with peptic ulcer bleed. Epidemiology. 1999;10:228–232.PubMedCrossRef García Rodríguez L, Ruigómez A. Secondary prevention of upper gastrointestinal bleeding associated with maintenance acid-suppressing treatment in patients with peptic ulcer bleed. Epidemiology. 1999;10:228–232.PubMedCrossRef
11.
go back to reference Walker AM. Observation and inference. An introduction to the methods of epidemiology. Newton Lower Falls: Epidemiology Resources Inc.; 1991. Walker AM. Observation and inference. An introduction to the methods of epidemiology. Newton Lower Falls: Epidemiology Resources Inc.; 1991.
12.
go back to reference Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158:915–920.PubMedCrossRef Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158:915–920.PubMedCrossRef
13.
go back to reference Hernán M, Brumback B, Robins J. Marginal structural models to estimate the joint effect of non randomized treatments. J Am Stat Assoc. 2001;96:440–448.CrossRef Hernán M, Brumback B, Robins J. Marginal structural models to estimate the joint effect of non randomized treatments. J Am Stat Assoc. 2001;96:440–448.CrossRef
14.
go back to reference Hernán M, Robins J. Instrumental variables for causal inference: an epidemiologist dream? Epidemiology. 2006;17:360–372.PubMedCrossRef Hernán M, Robins J. Instrumental variables for causal inference: an epidemiologist dream? Epidemiology. 2006;17:360–372.PubMedCrossRef
15.
go back to reference Hernan MA, Hernandez-Diaz S. Beyond the intention-to-treat in comparative effectiveness research. Clin Trials. 2012;9:48–55.PubMedCrossRef Hernan MA, Hernandez-Diaz S. Beyond the intention-to-treat in comparative effectiveness research. Clin Trials. 2012;9:48–55.PubMedCrossRef
16.
go back to reference Bourke A, Dattani H, Robinson M. Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care. 2004;12:171–177.PubMed Bourke A, Dattani H, Robinson M. Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care. 2004;12:171–177.PubMed
19.
go back to reference Margulis AV, Garcia Rodriguez LA, Hernandez-Diaz S. Positive predictive value of computerized medical records for uncomplicated and complicated upper gastrointestinal ulcer. Pharmacoepidemiol Drug Saf. 2009;18:900–909.PubMedCrossRef Margulis AV, Garcia Rodriguez LA, Hernandez-Diaz S. Positive predictive value of computerized medical records for uncomplicated and complicated upper gastrointestinal ulcer. Pharmacoepidemiol Drug Saf. 2009;18:900–909.PubMedCrossRef
20.
go back to reference Andersen IB, Jorgensen T, Bonnevie O, Gronbaek M, Sorensen TI. Smoking and alcohol intake as risk factors for bleeding and perforated peptic ulcers: a population based cohort study. Epidemiology. 2000;11:434–439.PubMedCrossRef Andersen IB, Jorgensen T, Bonnevie O, Gronbaek M, Sorensen TI. Smoking and alcohol intake as risk factors for bleeding and perforated peptic ulcers: a population based cohort study. Epidemiology. 2000;11:434–439.PubMedCrossRef
21.
go back to reference Lanas A, Remacha B, Esteva F, Sainz R. Risk factors associated with refractory peptic ulcers. Gastroenterology. 1995;109:1124–1133.PubMedCrossRef Lanas A, Remacha B, Esteva F, Sainz R. Risk factors associated with refractory peptic ulcers. Gastroenterology. 1995;109:1124–1133.PubMedCrossRef
22.
go back to reference Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1991;115:787–796.PubMedCrossRef Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1991;115:787–796.PubMedCrossRef
23.
go back to reference Patrono C, Coller B, Dalen J, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest. 2004;126:234S–264S.PubMedCrossRef Patrono C, Coller B, Dalen J, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest. 2004;126:234S–264S.PubMedCrossRef
24.
go back to reference Fitzgerald G, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345:433–442.PubMedCrossRef Fitzgerald G, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345:433–442.PubMedCrossRef
25.
go back to reference Laine L. Review article: the effect of Helicobacter pylori infection on non-steroidal anti-inflammatory drug-induced upper gastrointestinal tract injury. Aliment Pharmacol Ther. 2002;16:34–39.PubMedCrossRef Laine L. Review article: the effect of Helicobacter pylori infection on non-steroidal anti-inflammatory drug-induced upper gastrointestinal tract injury. Aliment Pharmacol Ther. 2002;16:34–39.PubMedCrossRef
26.
go back to reference Hopkins R, Girardi L, Turney E. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology. 1996;110:1244–1252.PubMedCrossRef Hopkins R, Girardi L, Turney E. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology. 1996;110:1244–1252.PubMedCrossRef
Metadata
Title
Risk of Complications After a Peptic Ulcer Diagnosis: Effectiveness of Proton Pump Inhibitors
Authors
Sonia Hernández-Díaz
Elisa Martín-Merino
Luis A. García Rodríguez
Publication date
01-06-2013
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 6/2013
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-013-2561-9

Other articles of this Issue 6/2013

Digestive Diseases and Sciences 6/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.